Rabia Gurses Ozden - 25 Feb 2025 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Signature
/s/ Aneta Fergson, Attorney-in-Fact
Issuer symbol
ADVM
Transactions as of
25 Feb 2025
Net transactions value
$0
Form type
4
Filing time
27 Feb 2025, 16:05:13 UTC
Previous filing
06 Aug 2024
Next filing
20 Jun 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADVM Common Stock Award $0 +8,125 $0.000000 8,125 25 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Award $0 +48,750 $0.000000 48,750 25 Feb 2025 Common Stock 48,750 $4.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-third (1/3rd) of the total number of shares subject to this award on each anniversary of March 1, 2025 (the "Vesting Commencement Date"), so that all of the shares subject to the RSUs are vested on the third (3rd) annual anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each vesting date.
F2 Twenty-five percent (25%) of the total number shares subject to the Option shall vest and become exercisable one year after the Vesting Commencement Date, and one-forty-eighth (1/48th) of the total number of shares subject to the Option shall vest and become exercisable each month thereafter, so that all of the shares subject to the Option are vested and exercisable on the fourth (4th) anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each vesting date.